Philip Monteleone profile picture
315 464-5294

Philip Monteleone, MD

CURRENT APPOINTMENTS

Associate Professor of Pediatrics

SPECIALTIES

Pediatric Hematology/Oncology

LANGUAGES

English

PATIENT TYPE

Children

CLINICAL BACKGROUND AND MY APPROACH TO CARE

Adolescent and Young Adult cancer diagnosis and treatment

Thrombosis in Children

Pediatric Cancers, esp leukemias, brain tumors and sarcomas

CLINICAL TRIALS

ANHL1931 A Randomized Phase 3 Trial of Nivolumab (NSC# 748726, IND# 125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma
Read more
ACNS1833 - A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF!)
Read more
ARST1921: A Safety, Pharmacokinetic and Efficacy Study of a y-Secretase Inhibitor, Nirogacestat (PF-03084014; IND#146375), in Children and Adolescents with Progressive, Surgically Unresectable Desmoid Tumors
Read more
ANBL1232 - Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma
Read more
ALTE11C2 - Health Effects after Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-related Cardiomyopathy
Read more
APEC14B1 - Project:EveryChild A Registry, Eligibility Screening, Biology and Outcome Study
Read more
AAML1531 - Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Read more
ARST1431 - A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC#683864, IND#122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
Read more
AGCT1531 - A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
Read more
APEC1621 - NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)
Read more
AALL1631 - International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones
Read more
ACNS1422 - A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Read more
AHEP1531 - Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Read more
AGCT1532 - A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumors UPSTATE IRB #: NCI CIRB: AGCT1532
Read more
AREN1721 - A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Axitinib or Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups
Read more
ACNS1721 - A Phase 2 Study of Veliparib (ABT-888, IND#139199) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide in Patients with Newly Diagnosed High-Grade Glioma (HGG) without H3 K27M or BRAFV600E Mutations
Read more
ANBL1821 - A Phase 2 Randomized Study of Irinotecan/ Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# 141913) in Children with Relapsed, Refractory or Progressive Neuroblastoma
Read more
AALL1731 - A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down Syndrome BLymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)
Read more
S1826- A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Read more
ACNS1723 - A Phase 2 Study of Dabrafenib (NSC#763760) with Trametinib (NSC#763093) after Local Irradiation in Newly Diagnosed BRAFv600 - Mutant High-Grade Glioma (HGG) (IND #145355)
Read more
AALL1732 - A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND# 133494, NSC# 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Read more
ASH RC COVID-19 Registry for Hematologic Malignancies
Read more
ANBL1531 - A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)
Read more
ADVL18P1 - An Open Label Feasibility Study to Assess the Safety and Pharmacokinetics of Enasidenib in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia (R/R-AML) with an Isocitrate Dehydrogenase-2 (IDH2) Mutation
Read more
AAML1831 - A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations
Read more
National Registry of Pediatric Cancer Patients Diagnosed with COVID-19
Read more
E4412 - A Phase 1 Study with an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin
Read more
ALTE2031 - StepByStep: A Randomized Trial of a Mobile Health and Social Media Physical Activity Intervention among Adolescent and Young Adult Childhood Cancer Survivors
Read more
AALL1821 - A Phase 2 Study of Blinatumomab (NSC# 765986, IND# 125462) in Combination with Nivolumab (NSC# 748726, IND# 125462), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old with First Relapse
Read more
ANBL19P1 - A Pilot Study of Dinutuximab, Sargramostim (GMCSF), and Isotretinoin in Combination with Irinotecan and Temozolomide in the Post-Consolidation Setting for High-Risk Neuroblastoma
Read more
AREN1921 - Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
Read more
AALL1621: A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND#TBD) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
Read more
A021502 - Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
Read more
ALTE07C1 - Neuropsychological, Social, Emotional and Behavioral Outcomes in Children with Cancer
Read more
ALTE05N1 - Umbrella Long-Term Follow-Up Protocol
Read more
ALTE03N1 - Key Adverse Events Following Childhood Cancer
Read more
AREN03B2 - Renal Tumors Classification, Biology and Banking Study
Read more
ANBL00B1 - Neuroblastoma Biology Studies
Read more

DISEASES & CONDITIONS TREATED

Acute & Chronic Diseases and Conditions in Pediatric Patients
Anemia
Bleeding Disorders
Blood Clots
Childhood Cancers
Langerhans Cell Histiocytosis (LCH)
Sickle Cell Disease

TREATMENTS / SERVICES

Blood Transfusion
Bone Marrow Aspiration
Bone Marrow Biopsy
Chemotherapy
Lumbar Puncture

CLINICAL LOCATIONS

Upstate Cancer Center
750 East Adams Street
Syracuse, NY 13210
315 464-5294

CLINICAL SECTION AFFILIATIONS

Pediatrics
Hematology and Oncology

CURRENT HOSPITAL PRIVILEGES

Upstate University Hospital
Crouse Hospital